Bayer Aktiengesellschaft

Bayer Healthcare LLC

Rwth Aachen

Fujifilm Visualsonics, Inc.

Nano4imaging Gmbh

Fabian Kiessling

Dieter Zopf

Lars Röse

Sabine Hoff

Wiltrud Lederle

Dennis Doleschel

Nihan Güvener

Paul Borm

Twan Lammers

Jozef Cremers

Stanley Fokong Nyongamsen

Katrin Suppelt

The present invention relates to pharmaceutical compositions and combinations comprising regorafenib or its hydrate, solvate, metabolite or pharmaceutically acceptable salt or a polymorph thereof and a PD-1/PD-L1(2) inhibitor for treating, preventing or managing diseases and conditions including hyperproliferative disorders such as cancer in humans and other mammals.

Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer

The invention relates to the use of tetrapyrroles conjugated compounds as contrast agent in magnetic resonance imaging (MRI). In particular conjugates of natural hemin that can be embedded in gels and implants to image local delivery in MRI.

Tetrapyrroles conjugates as MRI contrast agent

The invention provides a multimodal ultrasound and photoacoustic contrast agent based on polymeric microparticles having a gas core and carrying at least one photoacoustic agent in its shell that stabilizes the gas core, for use in ultrasound and photoacoustic imaging. Such multimodal ultrasound and photoacoustic contrast agent is also suitable as a carrier of drugs and for use in photodynamic therapy, and for tissue imaging ex vivo.

Multimodal ultrasound and photoacoustic contrast agent based on polymeric microparticles

Growing community of inventors

Aachen, Germany

Fabian Kiessling